Heparin Sodium; Taurolidine Patent Expiration

Heparin Sodium; Taurolidine is used for preventing catheter-related bloodstream infections in hemodialysis patients. It was first introduced by Cormedix Inc in its drug Defencath on Nov 15, 2023.


Heparin Sodium; Taurolidine Patents

Given below is the list of patents protecting Heparin Sodium; Taurolidine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Defencath US11738120 Synthesis of taurolidine, purity profiles and polymorphs Apr 15, 2042 Cormedix
Defencath US7696182 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin May 16, 2025 Cormedix
Defencath US8541393 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin Nov 02, 2024

(Expired)

Cormedix
Defencath US9339036 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin Nov 02, 2024

(Expired)

Cormedix



Heparin Sodium; Taurolidine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List